NBI-98854-HD3005: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease

Project: Research project

StatusActive
Effective start/end date1/13/201/13/23

Funding

  • Huntington Study Group Ltd. (NBI-98854-HD3005)
  • Neurocrine Biosciences, Inc. (NBI-98854-HD3005)